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Abstract
Background: Recent research has demonstrated that circulating peripheral blood mononuclear fractions (PBMC)
containing haematopoietic stem (HSC)/progenitor cells have the potential to play a crucial role in regenerative
medicine strategies. Work in our laboratory has shown that a peripheral blood mononuclear cell fraction (PBMC)
enhances cartilage repair in an osteochondral defect model in sheep and has a significant effect on cells in the
joint niche. In order to obtain PBMC rich blood containing HSCs for further studies, we have performed, for the
first time, apheresis on adult sheep.
Results: Subcutaneous granulocyte-colony stimulating factor (G-CSF) was used to mobilise white blood cells and continual
flow apheresis was performed on 8 sheep under general anaesthetic. There were no observable side effects, although a
marked tendency for blood clotting during the procedure was noted. The administration of G-CSF for 3 days increased the
white blood cell (WBC) count in the peripheral blood from to 6.7 ± 2.1 × 106/ml to 16.1 ± 5.0 × 106/ml. Following apheresis,
the WBC numbers in the apheretic product increased to 38.5 ± 27.6 × 106/ml, comprised of a significant increase in
neutrophils and PBMC (from 5.25 ± 1.8 × 106/ml following G-CSF stimulation to 27.5 5 ± 27.6 × 106/ml). There was a mean
of 2.1% CD34 + ve cells and 95.5% CD45 + ve cells in the apheretic product.
Conclusions: This study describes the administration of G-CSF and subsequent apheresis in adult sheep. The technique is
safe when performed as described with no observable side effects. The technique permits collection of an increased WBC
fraction containing neutrophils and PBMC in adult sheep. This apheretic product contains CD34 + ve cells, representing an
HSC/progenitor population for use in in vivo and in vitro experiments.
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Background
The repair of articular cartilage defects remains challen-
ging and all currently available methods have their dis-
advantages. In addition to autologous chondrocytes, a
number of cell types have been proposed as stimulators
or contributors to repair either alone or in combination.
We have described the successful use of a peripheral
blood mononuclear cell fraction (PBMC) to enhance
cartilage repair in an ovine osteochondral defect model
[1]. This study showed that isolated PBMC had effects
on migration and differentiation of both chondrocytes
and mesenchymal stromal cells (MSC) [2, 3]. PBMC
populations contain a number of cell types, including
peripheral haematopoietic stem cells (HSC) [4], derived
from the bone marrow. CD34 + ve HSC are widely used
in regenerative medicine to treat malignant and non ma-
lignant haematopoetic disorders [5] and, increasingly,
are being used in regenerative medicine strategies to
treat disorders of other body systems [6]. Traditionally
HSC were harvested directly from the bone marrow for
bone marrow transplantation; however, automated re-
trieval of a peripheral blood progenitor cell (PBPC) frac-
tion for this purpose using an apheresis procedure is
now standard clinical practice [7]. The technique is
based on the mobilisation of bone marrow cells into the
peripheral blood by the administration of exogenous
granulocyte colony stimulating factor (G-CSF) [8]. Many
studies have described the use of apheresis to collect G-
CSF stimulated PBMC in man and apheresis has been
described in a number of animal species including dogs
[9, 10], monkeys [11] and swine [12].
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In order to continue investigating the effect of PBMC
and PBPC on the healing of joint surface defects in ex-
perimental ovine models, we have performed apheresis
in adult sheep to provide concentrated populations of
peripheral blood cells for in vitro and in vivo research.
In this paper we describe the use of G-CSF to stimulate
the bone marrow niche, the method of apheresis in
sheep and the cell types harvested.
Methods
Animals
Eight 3 year-old (adult) healthy Welsh Mountain female
sheep weighing 40-42 kg underwent apheresis. The ani-
mals were purchased from a Licenced Supplier specific-
ally for this study. All animal procedures were carried
out in accordance with the regulations as set out in the
Animal [Scientific Procedures] Act 1986. This study
received approval from both the Animal Welfare and
Ethical Review Board, Cambridge University and the UK
Home Office (Project Licence number 70/8165).
Donor preparation
Animals were treated with rhG-CSF (Neupogen, Amgen)
5 mg/kg subcutaneously once a day for 3 days prior to
apheresis with the final dose being administered 2 h be-
fore apheresis commenced [13]. Blood samples collected
into EDTA were obtained prior to commencing rhG-
CSF administration and immediately prior to apheresis
and complete blood counts (CBC) were performed to es-
tablish haematological values using an automated
haematology analyser.
Apheresis
A 20 g intravenous catheter was placed into the cephalic
vein and anaesthesia induced with a single intravenous
bolus of 3 mg/kg alfaxalone (Alfaxan, Jurox). This cath-
eter was secured and subsequently used as the fluid re-
turn portal during apheresis. Sheep were intubated and
maintained on isofluorane. Animals were placed in dor-
sal recumbency and jugular venous access obtained via
the integral cannula of the closed system apheresis tub-
ing kit. At the completion of apheresis, the jugular can-
nula and cephalic catheter were removed and the
animals were allowed to recover normally, prior to being
replaced into their pens.
Apheresis was performed using a Cobe Spectra
(Terumo-BCT) with a disposable double needle closed
system apheresis tubing kit. The tubing kit and collec-
tion chambers were primed with 50 ml acid-citrate-
dextrose A (ACD-A, Biomet, USA) anticoagulant and
0.9% saline. PBPC collections were performed on the
basis of individual data (body weight and haematocrit).
This data, fed into the CobeSpectra at the start of the
procedure, automatically established each animal’s total
blood volume, the optimal and maximal pump rates and
anticoagulant flow rate. Manually varying the plasma
pump speed allowed adjustments of the collection prod-
uct colour and flow rate. A colourgram was used to ver-
ify collection of PBMC products.
Throughout apheresis, the body temperature of the ani-
mals was monitored to ensure that the temperature
remained within normal limits (38.3–39.8). Animals were
positioned on a heat retaining mat to reduce heat loss
onto the underlying surface and maintain temperature in
the physiological range; also, animals were covered with
blankets to retain body heat. To avoid ACDA-A solution
induced hypocalcaemia, 40 ml of a 10% calcium gluconate
solution was administered either subcutaneously during
apheresis (n = 4) or mixed with blood and returned intra-
venously throughout the procedure via the cephalic vein
(n = 3). Apheresis was stopped when 35 ml apheretic prod-
uct and 30 ml plasma had been collected. Once the flow-
back was completed the animal was allowed to recover.
Apheretic product analysis
A CBC was made of the apheretic product and flow cy-
tometry was used to quantify CD34 and CD45 positive
cells in the apheretic samples. Cells were stained with
mouse anti-sheep CD45 FITC (0.001 mg mL−1;
MCA2220F, AbD Serotec, UK) and mouse anti-sheep
CD34 (0.005 mg mL−1; (AM32448PU-N, Acris/Origene
Europe, Germany) [14] conjugated to FITC using FITC
Fast Conjugation Kit (Abcam, UK) in staining buffer.
Cells were also stained with an equivalent concentration
of IgG controls: mouse IgG1-FITC (MCA928F, AbD
Serotec, UK) and mouse IgG2a FITC (ab81197, Abcam,
UK). Dead cells were excluded based on fluorescence
using a viability stain (AquaZombie, Biolegend). Cellular
staining was measured using a BD LSR-Fortessa with BD
FACSDiva software. Data was analysed using Beckman
Coulter Kaluza software (v1.2).
Statistical analysis
Results are expressed as mean ± standard deviation.
Comparisons between cell numbers at different experi-
mental points in the animals was determined by one
way ANOVA using Graph Pad prism. A p value of < 0.05
was considered statistically significant.
Results
Effects of rhG-CSF treatment
No obvious signs of any adverse effects that have been
reported in humans [15] were observed in the sheep i.e.
there was no allergic reaction, lameness reflecting bone
pain or reduction in food or water intake.
CBC were performed in peripheral blood before G-
CSF administration and immediately prior to apheresis.
Prior to G-CSF administration, the mean WBC
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concentration was 6.74 ± 2.06 × 106/ml. Following the ad-
ministration of G-CSF the mean WBC concentration was
16.1 ± 5.0 × 106/ml, a statistically significant 238% increase
(Fig. 1). Mean red blood cell (RBC) concentrations prior
to G-CSF administration were 7.7 ± 1.7 × 106/ml, with
RBC concentrations post-G-CSF administration signifi-
cantly decreasing to 6.4 ± 1.6 × 106/ml (Fig. 2).
Individual WBC types were quantified to identify
which cell types were being stimulated by G-CSF.
Neutrophils and PBMC (lymphocytes +monocytes) were
significantly increased following G-CSF treatment, no
significant alteration was seen in the granulocyte popula-
tion (eosinophils + basophils). Neutrophils increased from
3.1 ± 2 × 106/ml pre-treatment to 10.5 ± 4.2 × 106/ml post-
treatment, whilst PBMC increased from 3.4 ± 0.6 pre-
treatment to 5.2 ± 1.8 post-treatment. (Fig. 3).
One animal did not apparently respond to the adminis-
tration of G-CSF. In this animal, the pre-G-CSF WBC
count was 7.10 × 106/ml but, following the administration
of G-CSF, the WBC count had fallen to 3.9 × 106/ml.
Apheresis procedure
Seven of the eight animals completed the apheresis.
In one sheep, rapid and repeated clotting of venous
blood within the cannula and tubing at the start of
apheresis necessitated abandoning the procedure. In
addition, 2 further animals produced blood clots in
the cannula and/or tubing immediately upon starting
blood withdrawal by the Cobe Spectra. In these
animals, replacement catheters and heparin saline
flushes were required to continue the apheresis
procedure in the initial stages. The mean time
required for collection in the 7 sheep was 93 min ±
12 min to obtain 35 ml apheresis product and 30 ml
plasma.
Fig. 1 Total white blood cell (WBC) numbers in whole blood before
(Pre-GCSF) (n = 8) and after administration of G-CSF (Post-GCSF)
(n = 8) and in the apheretic product (n = 7). *Significantly different
from Pre-GCSF value, **Significantly different from Pre- and
Post- GCSF values. P < 0.05. Values ×106/ml blood
Fig. 2 Total red blood cell (RBC) numbers in whole blood before
(Pre-GCSF) (n = 8) and after administration of G-CSF (Post-GCSF)
(n = 8) and in the apheretic product (n = 7). *Significantly different
from Pre-GCSF value, **Significantly different from Pre- and
Post- GCSF values. P < 0.05. Values ×106/ml blood
Fig. 3 Numbers of neutrophils in in whole blood before (Pre-GCSF)
(n = 8) and after administration of G-CSF (Post-GCSF) (n = 8) and in
the apheretic product (n = 7)
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Effects of apheresis
Hypothermia was present in 1/7 sheep upon cessation of
the procedure. This animal was immediately covered
with blankets and placed into a warmed recovery area
until stable. No signs of hypocalcaemia (licking, agitation
or tremors in the absence of low body temperature)
were detected in any sheep during the procedure or
post-procedure.
Apheresis cell yields
The final collection volume was approximately 35 ml
in all animals. Following apheresis WBC concentra-
tions had risen significantly from a pre-apheresis
value of 16.1 ± 5.03 × 106/ml to 38.5 ± 27.6 × 106/ml
and RBC concentration had significantly decreased
from 6.4 ± 1.6 × 106/ml to 1.9 ± 1.0 × 106/ml. When in-
dividual cell types were quantified, the concentration
of neutrophil in the apheretic product was reduced
pre-apheresis (10.5 ± 4.2 × 106/ml compared to post-
apheresis of 6.4 ± 4) (Fig. 3). However, a significant in-
crease in PBMC was seen. When all 7 animals were
included in the analysis, including the non-responder,
PBMC concentrations rose from 5.2 ± 1.8 × 106/ml pre-
apheresis to 27.5 ± 23.9 × 106/ml post-apheresis. (Fig. 4).
Using flow cytometry, the number of CD34+ and
CD45+ cells in the apheresis product was measured. In
the apheretic product 2.71 ± 2.3% of nucleated cells were
CD34 + ve (Fig. 5.)
Discussion
This report documents for the first time the successful
concentration and collection of PBMC in sheep using
automated apheresis and demonstrates that the proced-
ure is a clinically safe method of obtaining a cell product
enriched for PBMC containing CD34+ cells that did not
pose significant technical difficulties.
Venous access was obtained via the jugular vein with
the cephalic vein acting as the return portal. The apher-
esis machine was primed with saline rather than pre-
collected blood as recommended in paediatric patients
and small animal apheresis [9, 16]. In these smaller pa-
tients, priming with blood is required for successful
apheresis as the extracorporeal circulating blood is a sig-
nificant percentage of blood volume. In this study the
sheep were sufficiently large (40-42 kg) that the haemo-
dilution caused by the addition of saline to the circula-
tion at the commencement of the cellular collection was
not significant.
In 1/8 animals rapid repeated clotting of blood led to
abandonment of the procedure in that individual. In 2
other animals clotting at the start of the procedure ne-
cessitated rapid placing of alternate catheters and/or
flushing of tubing with heparin to remove blood clots
before the pump could draw in the blood with sufficient
pressure for effective centrifugation. The reason for such
vigorous coagulation in 3/8 animals is not known. A
study on interspecies difference in coagulation profiles
reported that sheep had a similar clotting time and en-
dogenous thrombin potential to humans [17] and so the
response to the initial connection to the Cobe Spectra
could not have been predicted. The appearance of clots
coincided with the initial pressure from the machine
within the vein to draw blood from the animal. Clotting
is more likely at the beginning of the procedure as this
is when the least amount of anticoagulant is distributed
systemically. We recommend that particular attention is
paid to the placing of the withdrawal portal in sheep
undergoing apheresis and that all catheters/cannulas/
tubing are primed with heparin prior to drawing blood.
In order to increase the numbers of circulating WBC
containing the desired PBMC fraction, G-CSF was ad-
ministered to the sheep prior to apheresis. G-CSF is a
haematopoetic cytokine produced primarily by bone
marrow stromal cells that acts, at higher doses, by
stimulating the differentiation of several haematopoetic
progenitors including CD34+ cells. In this study we ad-
ministered 5 mg/kg rhG-CSF subcutaneously, daily for
3 days prior to apheresis. In a previous report this was the
optimum dose for mobilisation of ovine WBC [13] and
gave a peak response on day 3 of mobilisation, after which
time, the total WBC dropped markedly. In this study, the
sheep had a starting WBC count of 4.45 × 106/ml, which
rose to a post-GCSF value of approximately 13.5 × 106/ml)
Fig. 4 Numbers of Peripheral blood mononuclear cells (PBMC) in
whole blood before (Pre-GCSF) (n = 8) and after administration of
G-CSF (Post-GCSF) (n = 8) and in the apheretic product (n = 7).
*Significantly different from Pre- and Post- GCSF values. P < 0.05.
Values ×106/ml blood
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[13]. These blood results mirror very closely the values we
report in this paper and, coupled with the observation that
rhG-CSF did not cause any adverse clinical effects in any
of our sheep, support the use of commercially available
rhG-CSF for the mobilisation of sheep WBC cells in the
circulation. Of the 8 sheep treated with rhG-CSF one ani-
mal did not show an increase in WBC. In the other publi-
cation that reports the use of rhG-CSF in sheep, 1/3
animals did not respond. It has been reported that G-CSF
based mobilisation regimes have a 5–30% failure rate
among healthy individuals [18], with various factors being
associated with a poor response to G-CSF in human pa-
tients, including age of patient, type of G-CSF used and
prior exposure to other drugs. The reasons for poor mo-
bilisation in animals are unknown, although they are likely
to be similar.
Stimulation of the bone marrow using G-CSF and sub-
sequent apheresis lead to a significant increase in WBC
numbers and a significant decrease in RBC numbers in
the apheretic product compared to unstimulated periph-
eral blood and peripheral blood obtained immediately
prior to the apheresis technique. However, we did not
find that the post-G-CSF WBC concentration was a pre-
dictor of apheretic product WBC concentration as has
been reported in the dog [9]. Analysis of the cell types
contributing to the increase in WBC numbers in the
sheep reported here showed that neutrophils and PBMC
were the cell types that were significantly increased in
the apheretic product.
The PBMC fraction of blood is of particular interest in
regenerative medicine as it contains HSC and progenitor
cell populations. Whilst these progenitor cells have trad-
itionally been used to treat malignant and non malignant
haematopoetic disorders [5], they have also been used in
regenerative medicine strategies to treat disorders of other
body systems, including orthopaedic disease [6, 19] How-
ever, the identification of stem and progenitor cell
populations in peripheral blood and apheretic products in
veterinary species is not straightforward, due both to po-
tential differences in stem cell CD designation and func-
tion between species and the availability of suitable
reagents to characterise CD markers. In man, there is a
recognised population of CD34 + ve cells that have stem/
progenitor potential and are used for clinical transplant-
ation [14]. In the sheep CD34 + ve cells have also been
shown to have haematopoetic potential [20] and so CD34
appears to be an appropriate marker in this species, as
well as man, for HSC. In this study, using flow cytometry
and a sheep specific anti-CD34 antibody [14], we have
shown that, 2.7% of the apheretic product was CD34 + ve.
This figure is similar to the 1.5% reported in other studies
[21] and supports our methodology.
Conclusions
In conclusion this study has demonstrated that apheresis
can be used in the sheep safely and without risk to the
animal. The administration of G-CSF and subsequent
apheresis provides a neutrophil and PBMC rich collec-
tion product containing > 2% of CD34 + ve cells that can
be used for further in vivo or in vitro experimental
investigations.
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